BRPI0406057B1 - Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante - Google Patents

Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante Download PDF

Info

Publication number
BRPI0406057B1
BRPI0406057B1 BRPI0406057-1A BRPI0406057A BRPI0406057B1 BR PI0406057 B1 BRPI0406057 B1 BR PI0406057B1 BR PI0406057 A BRPI0406057 A BR PI0406057A BR PI0406057 B1 BRPI0406057 B1 BR PI0406057B1
Authority
BR
Brazil
Prior art keywords
amblyomin
tumor
activity
cells
recombinant protein
Prior art date
Application number
BRPI0406057-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Ana Marisa Chudzinski Tavassi
Durvanei Augusto Maria
Isabel De Fátima Correia Batista
Paulo Lee Ho
Original Assignee
União Química Farmacêutica Nacional S/A
Ana Marisa Chudzinski Tavassi
Fundação De Amparo À Pesquisa Do Estado De São Paulo - Fapesp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by União Química Farmacêutica Nacional S/A, Ana Marisa Chudzinski Tavassi, Fundação De Amparo À Pesquisa Do Estado De São Paulo - Fapesp filed Critical União Química Farmacêutica Nacional S/A
Priority to BRPI0406057-1A priority Critical patent/BRPI0406057B1/pt
Priority to JP2007531547A priority patent/JP4980220B2/ja
Priority to DK05782904.6T priority patent/DK1799707T3/da
Priority to CA2581001A priority patent/CA2581001C/en
Priority to CN2005800389926A priority patent/CN101142232B/zh
Priority to ES05782904T priority patent/ES2410160T3/es
Priority to PCT/BR2005/000185 priority patent/WO2006029492A1/en
Priority to EP05782904A priority patent/EP1799707B1/en
Priority to AU2005284615A priority patent/AU2005284615B2/en
Publication of BRPI0406057A publication Critical patent/BRPI0406057A/pt
Priority to US11/724,557 priority patent/US8440795B2/en
Priority to CA002680759A priority patent/CA2680759A1/en
Publication of BRPI0406057B1 publication Critical patent/BRPI0406057B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Insects & Arthropods (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0406057-1A 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante BRPI0406057B1 (pt)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0406057-1A BRPI0406057B1 (pt) 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
ES05782904T ES2410160T3 (es) 2004-09-15 2005-09-15 Inhibidor recombinante de tipo Kunitz
DK05782904.6T DK1799707T3 (da) 2004-09-15 2005-09-15 Rekombineret Kunitztypeinhibitor
CA2581001A CA2581001C (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor
CN2005800389926A CN101142232B (zh) 2004-09-15 2005-09-15 Kunitz型重组抑制剂
JP2007531547A JP4980220B2 (ja) 2004-09-15 2005-09-15 Ｋｕｎｉｔｚ型組換え阻害因子
PCT/BR2005/000185 WO2006029492A1 (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor.
EP05782904A EP1799707B1 (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor.
AU2005284615A AU2005284615B2 (en) 2004-09-15 2005-09-15 Kunitz-type recombinant inhibitor.
US11/724,557 US8440795B2 (en) 2004-09-15 2007-03-14 Kunitz-type recombinant inhibitor
CA002680759A CA2680759A1 (en) 2004-09-15 2008-03-14 Kunitz-type recombinant inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0406057-1A BRPI0406057B1 (pt) 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante

Publications (2)

Publication Number Publication Date
BRPI0406057A BRPI0406057A (pt) 2006-05-02
BRPI0406057B1 true BRPI0406057B1 (pt) 2021-10-26

Family

ID=36273230

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406057-1A BRPI0406057B1 (pt) 2004-09-15 2004-09-15 Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante

Country Status (10)

Country Link
US (1) US8440795B2 (enExample)
EP (1) EP1799707B1 (enExample)
JP (1) JP4980220B2 (enExample)
CN (1) CN101142232B (enExample)
AU (1) AU2005284615B2 (enExample)
BR (1) BRPI0406057B1 (enExample)
CA (2) CA2581001C (enExample)
DK (1) DK1799707T3 (enExample)
ES (1) ES2410160T3 (enExample)
WO (1) WO2006029492A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109976A1 (en) * 2007-03-14 2008-09-18 União Química Farmacêutica Nacional S/A Kunitz-type recombinant inhibitor
BRPI0406057B1 (pt) 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
NZ593815A (en) 2008-12-19 2013-05-31 Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
US8772238B2 (en) 2009-03-18 2014-07-08 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer
BR102018074043A2 (pt) * 2018-11-22 2020-06-02 Inst Butantan composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias
BR102018074037A2 (pt) * 2018-11-22 2021-05-11 Inst Butantan composto para direcionar entidades moleculares para o domínio intracelular de células neoplásicas, ingrediente farmacêutico ativo compreendendo o referido composto, composição farmacêutica, método para o diagnóstico, prognóstico e/ou tratamento de câncer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3006207C2 (de) * 1980-02-15 1982-10-21 Siemens AG, 1000 Berlin und 8000 München Elektrische Maschine mit einem Ständerblechpaket aus kornorientierten Blechen
DE3819078A1 (de) * 1988-06-04 1989-12-07 Hoechst Ag Amblyommin, ein neuer wirkstoff fuer die antikoagulationstherapie
BRPI0406057B1 (pt) 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante

Also Published As

Publication number Publication date
CA2581001C (en) 2011-05-03
US20090042786A1 (en) 2009-02-12
ES2410160T3 (es) 2013-07-01
WO2006029492A1 (en) 2006-03-23
DK1799707T3 (da) 2013-05-21
CN101142232A (zh) 2008-03-12
BRPI0406057A (pt) 2006-05-02
JP2008512992A (ja) 2008-05-01
AU2005284615A1 (en) 2006-03-23
JP4980220B2 (ja) 2012-07-18
US8440795B2 (en) 2013-05-14
CA2680759A1 (en) 2008-09-18
AU2005284615B2 (en) 2011-03-31
EP1799707A1 (en) 2007-06-27
CA2581001A1 (en) 2006-03-23
EP1799707B1 (en) 2013-03-27
CN101142232B (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
Moreau et al. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family
Beauchamp et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation
Jia et al. Function of disintegrin-like/cysteine-rich domains of atrolysin A: inhibition of platelet aggregation by recombinant protein and peptide antagonists
Cicardi et al. C1 inhibitor: molecular and clinical aspects
Huber-Lang et al. Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions
US8440795B2 (en) Kunitz-type recombinant inhibitor
Randolph et al. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli
Bieth Human neutrophil elastase
Ranasinghe et al. A novel coagulation inhibitor from Schistosoma japonicum
Brito et al. The Kallikrein Inhibitor from Bauhinia bauhinioides (BbKI) shows antithrombotic properties in venous and arterial thrombosis models
Huang et al. Low-dose hydralazine improves endotoxin-induced coagulopathy and multiple organ dysfunction via its anti-inflammatory and anti-oxidative/nitrosative properties
Li et al. LCTX-F2, a novel potentiator of coagulation factors from the spider venom of Lycosa singoriensis
Markwardt State-of-the-Art Review: antithrombotic agents from hematophagous animals
Hakim et al. Discoveries of serine protease inhibitors from scorpions
EP2134843A1 (en) Kunitz-type recombinant inhibitor
Matrane et al. Congenital Alpha-2 Antiplasmin Deficiency: a Literature Survey and Analysis of 123 Cases.
BRPI0200269B1 (pt) processo de purificação de proteínas solúveis das cerdas da l. obliqua com atividade ativadora de protrombina e uso da fração proteica
Monti Von Willebrand factor, ADAMTS13 and neutrophil extracellular traps: allies in cancer-associated thrombosis and tumor progression
BRPI0403882B1 (pt) sequência nucleotídica, sequência de aminoácidos, protease ativadora de protrombina recombinante (rlopap), processo para obter a mesma na forma monomérica, uso da mesma
Sumi et al. Purification of a new plasma inhibitor of kallikrein
CN106928334A (zh) 约安巨马陆抗血栓肽Joannsin及其应用
Berg et al. British Society for Haemostasis and
BRPI0704854B1 (pt) uso de inibidores da agregação plaquetária e da coagulação isolados de bauhinia sp.
TW200846356A (en) Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
Knight The role of PAR-1, PAR-2 and Tissue factor in the development of hepatic fibrosis

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61P 35/00 (2010.01), A61K 38/57 (2010.01), C12N 1

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/57 (2006.01), A61P 35/00 (2006.01), C12N 1

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.